27425-92-9 Usage
Description
DECAETHYLENE GLYCOL MONOMETHYL ETHER, also known as m-PEG10-alcohol, is a PEG (Polyethylene Glycol) linker that contains a hydroxyl group. This hydroxyl group allows for further derivatization or replacement with other reactive functional groups, making it a versatile compound in various chemical reactions and applications. The hydrophilic PEG spacer enhances solubility in aqueous media, which is beneficial for its use in different industries.
Uses
Used in Chemical Synthesis:
DECAETHYLENE GLYCOL MONOMETHYL ETHER is used as a reactant for the synthesis of functional vinyl ethers and radical alternating copolymers with chlorotrifluoroethylene. The hydroxyl group in m-PEG10-alcohol enables the formation of these copolymers, which can have various applications in different industries.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, DECAETHYLENE GLYCOL MONOMETHYL ETHER is used as a building block for the development of drug delivery systems. The hydrophilic PEG spacer improves the solubility and bioavailability of drugs, making it easier for them to be administered and absorbed by the body.
Used in Material Science:
DECAETHYLENE GLYCOL MONOMETHYL ETHER can be used in the development of new materials with specific properties. The hydroxyl group allows for the attachment of various functional groups, which can result in materials with tailored characteristics for specific applications.
Used in Cosmetics Industry:
In the cosmetics industry, DECAETHYLENE GLYCOL MONOMETHYL ETHER can be used as an ingredient in the formulation of personal care products. The hydrophilic nature of the PEG spacer can improve the solubility of other ingredients, enhancing the overall performance of the product.
Used in Environmental Applications:
DECAETHYLENE GLYCOL MONOMETHYL ETHER can be employed in the development of environmentally friendly materials and processes. The hydroxyl group can be used to attach functional groups that can help in the degradation or recycling of materials, contributing to a more sustainable industry.
Check Digit Verification of cas no
The CAS Registry Mumber 27425-92-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,7,4,2 and 5 respectively; the second part has 2 digits, 9 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 27425-92:
(7*2)+(6*7)+(5*4)+(4*2)+(3*5)+(2*9)+(1*2)=119
119 % 10 = 9
So 27425-92-9 is a valid CAS Registry Number.
InChI:InChI=1/C21H44O11/c1-23-4-5-25-8-9-27-12-13-29-16-17-31-20-21-32-19-18-30-15-14-28-11-10-26-7-6-24-3-2-22/h22H,2-21H2,1H3
27425-92-9Relevant articles and documents
Monodisperse oligoethylene glycols modified Camptothecin, 10-Hydroxycamptothecin and SN38 prodrugs
Deng, Tao,Mao, Xianglan,Xiao, Yan,Yang, Zhigang,Zheng, Xing,Jiang, Zhong-Xing
, p. 581 - 584 (2019/01/04)
Camptothecin, which represents a class of natural products with high anticancer activity, suffers low water solubility which hampers its clinic application. To address this issue, monodisperse polyethylene glycols were employed to modify this class of natural products, including Camptothecin, 10-Hydroxycamptothecin, and SN38. Through selective modification with a series of monodisperse polyethylene glycols, 31 Camptothecin derivatives, including 9 ethers and 22 carbonates, were prepared using a macrocyclic sulfate-based strategy with high efficacy. Monodisperse polyethylene glycols modification provided the Camptothecin derivatives with high purity and fine-tunable water solubility. Through the physicochemical and biological assays, a few novel prodrugs with good solubility, cytotoxicity, and valuable drug release profile were identified as promising anticancer drug candidates.
Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
-
, (2008/06/13)
Pharmaceutical compositions that include an insulin drug-oligomer conjugate, a fatty acid component, and a bile salt component are described. The insulin drug is covalently coupled to an oligomeric moiety. The fatty acid component and the bile salt component are present in a weight-to-weight ratio of between 1:5 and 5:1. Methods of treating an insulin deficiency in a subject in need of such treatment using such pharmaceutical compositions are also provided, as are methods of providing such pharmaceutical compositions.
Pharmaceutical compositions of drug-oligomer conjugates and methods of treating diseases therewith
-
, (2008/06/13)
Pharmaceutical compositions that include a drug-oligomer conjugate, a fatty acid component, and a bile salt component are described. The drug is covalently coupled to an oligomeric moiety. The fatty acid component and the bile salt component are present in a weight-to-weight ratio of between 1:5 and 5:1. Methods of treating diseases in a subject in need of such treatment using such pharmaceutical compositions are also provided, as are methods of providing such pharmaceutical compositions.
